Dr. Gnanamba V. Kondagunta, MD

Dr. Kondagunta practices at Crystal Run Healthcare Physicians in Middletown, New York.

Dr. Kondagunta's NPI, 1265403208, was assigned on January 29, 2006. Dr. Kondagunta graduated from Weill Cornell Medicine in 1998. Dr. Kondagunta holds New York license 215626.

Dr. Kondagunta's primary practice is Crystal Run Healthcare Physicians, at 155 Crystal Run Rd, Middletown, NY 10941 in Orange County. The practice phone is (845) 703-6999.

Dr. Kondagunta's primary practice is Crystal Run Healthcare Physicians in Middletown, New York. Dr. Kondagunta is also affiliated with Garnet Health Medical Center. The medical group on file is Crystal Run Healthcare. Dmand AI also links Dr. Kondagunta to 3 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kondagunta practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kondagunta's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kondagunta is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kondagunta's licenses on file in 2 states: New York and Ohio.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Kondagunta treats.

CMS data shows 49,242 Medicare services from Dr. Kondagunta across 60 procedure codes in 2024, for 795 Medicare patients. Medicare paid $1,136,644 for them.

CMS counts 795 Medicare patients who saw Dr. Kondagunta in 2024. The largest group is 65 to 74, with 324 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kondagunta's median patient age at 68, with 67% women.

In 2024, Dr. Kondagunta wrote 2,255 Medicare Part D claims for 381 patients. 77% of them were for generic drugs. CMS names the drug for 2,024 of them, across 36 drugs with 11 or more claims each, at $4,948,314 in total drug cost. In 2023, CMS named 1,660 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Kondagunta for performance year 2024, reported as part of a group. Dr. Kondagunta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kondagunta as offering telehealth.

Dmand AI links 23 papers to Dr. Kondagunta, published from 2006 to 2008. 2007 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Renal Cell. Dr. Kondagunta has published most often in J Clin Oncol. Dr. Kondagunta's most frequent co-authors are Robert J. Motzer, MD, Joel Sheinfeld, MD and Paul Russo, MD.

Dmand AI links Dr. Kondagunta to 4 clinical trials, 3 of them phase 2 studies. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Carcinoma, Embryonal. Memorial Sloan Kettering Cancer Center sponsors the most, 4.

CMS Open Payments shows 2 general payments to Dr. Kondagunta from 2 drug and device companies from 2017 to 2021. Food and beverage make up the largest share, 69% of the total. Amgen Inc. paid the most, $27.

Dmand AI lists 1 award for Dr. Kondagunta, most recently CMS Stage 1 EHR in 2012.

Dr. Kondagunta graduated from Weill Cornell Medicine in 1998. Dr. Kondagunta is a member of ASCO.

Dr. Kondagunta is in network with 19 carriers, including Aetna, Excellus BlueCross BlueShield and MVP Health Care. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.